Global Cell Therapy Pipeline Analysis

Publish Date:- Sep-2013       No Of Pages (220)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $2000Buy Now
Hard Copy Mail Delivery $2000 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


Global Cell Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of multiple disease based upon Cell Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the Cell Therapy associated with the various diseases.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cell Therapy based drug development process. Following parameters for each drug profile in development phase are covered in “Global Cell Therapy Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route • Drug Class

• ATC Codes


Global Cell Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of multiple disease based upon Cell Therapy. Research report covers all the ongoing drug development in various development phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Country of Development and detailed analysis on the development process. Insight for each drug profile in development phase enables the reader to identify and understand the Cell Therapy associated with the various diseases.

This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cell Therapy based drug development process. Following parameters for each drug profile in development phase are covered in “Global Cell Therapy Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route • Drug Class

• ATC Codes

1. Global Cell Therapy Market Overview



2. Cell Therapy Drug Development Phase: Research

  2.1 Overview

  2.2 Drug Profiles in Development Phase



3. Cell Therapy Drug Development Phase: Preclinical

  3.1 Overview

  3.2 Drug Profiles in Development Phase



4. Cell Therapy Drug Development Phase: Phase-I

  4.1 Overview

  4.2 Drug Profiles in Development Phase



5. Cell Therapy Drug Development Phase: Phase-I/II

  5.1 Overview

  5.2 Drug Profiles in Development Phase



6. Cell Therapy Drug Development Phase: Phase-II

  6.1 Overview

  6.2 Drug Profiles in Development Phase 



7. Cell Therapy Drug Development Phase: Phase-II/III

  7.1 Overview

  7.2 Drug Profiles in Development Phase



8. Cell Therapy Drug Development Phase: Phase-III

  8.1 Overview

  8.2 Drug Profiles in Development Phase



9. Cell Therapy Drug Development Phase: Registered

  9.1 Overview

  9.2 Drug Profiles in Development Phase



10. Marketed

  10.1 Overview

  10.2 Drug Profiles in Development Phase


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC code

• Designated Brand Name & Orphan Designation